HOME >> BIOLOGY >> NEWS
Studies of rare blood syndrome yield novel route to cancer

By carefully studying why a rare blood disorder responds to the anti-cancer drug Gleevec, researchers have discovered an entirely new mechanism that generates cancer-causing genes.

The study, published in the March 27, 2003, issue of the New England Journal of Medicine, shows that Gleevec is an effective treatment for hypereosinophilic syndrome (HES), a blood disorder that is nearly always fatal. According to the researchers, their studies suggest that HES should be reclassified by the World Health Organization from its current "gray-area" status as a "syndrome" to a form of cancer.

Senior authors of the article were D. Gary Gilliland, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital and Harvard Medical School, and Richard Stone at the Dana-Farber Cancer Institute (DFCI). Joint first authors on the paper were Jan Cools, a postdoctoral fellow in Gilliland's laboratory, and Daniel DeAngelo, who is also at DFCI and an instructor at Harvard Medical School.

HES is caused by overproliferation of a type of white blood cells called eosinophils. Physicians treat the syndrome with a combination of drugs and chemotherapy, said Gilliland, but eventually, the assault of eosinophils damages major organs, and causes the heart or lungs to fail, and ultimately results in death of most patients.

Recently, however, hints that the disorder might respond to Gleevec began to crop up in the medical literature. "There was a report of a single case of an HES patient treated with Gleevec and had what was described as a miraculous response," said Gilliland. "This anecdotal report was substantiated by a group of investigators that reported successful treatment in 4 of 5 additional HES patients, reported in the The Lancet (a British medical journal) last year.

Gleevec works by inhibiting enzymes called tyrosine kinases. When the activity of
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
26-Mar-2003


Page: 1 2 3 4

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies dispute ultraviolet effect on amphibian population declines
8. Studies of spiders silk reveal unusual strength
9. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
10. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
Cached News: